BIP Capital Partners
Primary Menu
Skip to content
HOME
About us
OUR TEAM
OUR HISTORY
ESG
BIP IV
investment approach
INVESTMENT APPROACH
INVESTMENT CHARACTERISTICS
portfolio
SELECTED INVESTMENTS
SELECTED EXITS
News
CONTACT
Enzymotec reports 4th quarter and full year 2014 unaudited financial results
Post navigation
Previous Post
LSP, one of BIP’s fund investments, has announced that its portfolio company Prosensa N.V. received tender offer from Biomarin
Next Post
Enzymotec reports second quarter 2015 results
